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Background: In many clinical trials designed to assess the efficacy of anticancer treatments, overall 
survival (OS) is often used as a primary endpoint despite its several points of weakness. 
Methods: This study evaluated the role of progression-free survival (PFS) in the first three 
lines of treatment as a potential surrogate endpoint of OS in patients with metastatic colorectal 
cancer (MCRC). One hundred and twenty patients with MCRC were enrolled in this study. The 
median PFS of the first-, second-, and third-lines of treatment and the OS were evaluated. The 
correlation between the time to progression and the OS was analyzed. The median PFS of the 
three lines of treatment were 8.5, 5, and 3 months, respectively. 
Results: The median OS was 32.4 months. A modest correlation was found between the PFS 
to the first-line treatment with Folfox–avastin and OS. Similar data were obtained with the 
second-line treatment. However, no correlation was found between the PFS and OS during the 
third-line treatment. The regression analysis revealed that PFS is predictive of OS. 
Conclusion: In brief, the PFS of the first- and second-lines of treatment could be a good can-
didate as a surrogate endpoint of OS in patients with MCRC.
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Introduction
Metastatic colorectal cancer (MCRC) is characterized by a very variable natural history. 
At the time of diagnosis, only 20–30% of patients have the disease confined to the 
liver. In the last 5 years, the role of chemotherapy in the treatment of MCRC has con-
siderably increased. Standard regimens used to treat patients with MCRC are based on 
chemotherapy drugs such as fluoropyrimidines, oxaliplatin, and irinotecan (which can 
be used in combination and sequentially) and monoclonal antibodies targeting vascular 
endothelial growth factor (VEGF) such as bevacizumab.1 On the other hand, in patients 
with RAS (both KRAS and NRAS) wild-type tumors, monoclonal antibodies targeting 
epidermal growth factor receptor (EGFR) such as cetuximab and panitumumab are used 
as single agents or in combination with chemotherapy.2 However, regimens related 
to the first- or second-line treatment have a paucity of effectiveness in the course 
of treatment. Only a minority of patients with MCRC can benefit from all agents.3 
In general, the combination of chemotherapy with targeted drugs, such as anti-VEGF 
and anti-EGFR monoclonal antibodies, gives better results.4 In fact, VEGF is one of 
the most important factors that regulate tumor angiogenesis which plays an important 
role in tumor progression, invasion, and metastasis to distant organs.5
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These therapeutic regimens showed a statistically signifi-
cant impact on overall survival (OS). To assess the efficacy 
of this anticancer treatment in clinical trials, the often used 
surrogate endpoint has been OS, but studies using the OS 
as the surrogate endpoint need a large number of patients 
and an extremely long time of follow-up which can delay 
the evaluation of treatment efficacy. The term surrogate 
endpoint was defined by The Biomarker Definitions Work-
ing Group as: 
a biomarker that is intended to substitute for a clinical 
end point, and is expected to predict clinical benefit or 
harm (or lack of benefit or harm) based on epidemiologic, 
therapeutic, pathophysiologic, or other scientific evidence.6
In their meta-analysis, Cremolini et al7 confirmed the role of 
progression-free survival (PFS) as a reliable surrogate for OS, 
thus justifying the surrogacy of PFS as a primary endpoint 
in first-line studies in MCRC. Furthermore, the PFS has 
also been tested in second- and further-lines of treatment of 
several targeted agents producing significant results.
A meta-analysis by Shi et al describes an existent but 
reduced relationship between PFS and OS in a large set of 
first-line MCRC trials. This meta-analysis suggests that a 
significant OS benefit from a single line of treatment will be 
increasingly challenging for a long post-progression survival 
times with a greater chance for heterogeneous patient treat-
ment. For this reason, PFS remains an appropriate endpoint 
for first-line trials in MCRC.8
In our retrospective study, the purpose was to evalu-
ate if PFS of the three lines of treatment can be a primary 
endpoint of OS in patients with MCRC. Consequently, this 
surrogate endpoint will allow us to reach a shorter time 
with a small number of patients to make new options more 
rapidly available.
Materials and methods
study design
This retrospective study analyzed 120 patients diagnosed 
with pathologically confirmed MCRC, between January 2013 
and March 2017 at the Medical Oncology Unit of the 
University of Palermo.
This study was approved by the ethics committee of the 
Azienda Ospedaliera Universitaria Policlinico “P. Giaccone” 
at Palermo, and all patients provided written consent to 
review their medical records. Clinical data were collected 
from patients who received all three lines of chemotherapy 
treatment as follows: first-line treatment with Folfox–avastin, 
second-line treatment with Folfiri–avastin,9 and third-line 
treatment with regorafenib.10
All patients enrolled in this study had to meet the fol-
lowing inclusion criteria: 1) histologically or cytologically 
confirmed diagnosis of MCRC according to the Response 
Evaluation Criteria in Solid Tumors (RECIST version 
1.1); 2) performance status of 0–2 according to the Eastern 
Cooperative Oncology Group; 3) clinical or radiological 
evidence of metastatic disease (number of lesions $1) and 
with an adequate liver, renal, and blood functionality; and 
4) patients who had RAS (both KRAS and NRAS) muta-
tion. Patients were excluded if they were 1) hypersensitive 
to chemotherapeutic drugs administered in the three lines 
of treatment and their excipients or other formulation 
components, 2) diagnosed with other malignancies (with 
the exception of properly treated basal cell carcinoma of 
the skin), and 3) suffering from serious comorbidities not 
adequately controlled by other ongoing therapies (eg, liver 
disease, diabetes, infections, and heart disease).
evaluation of the response and survival
Computerized tomography and magnetic resonance imaging 
were used to assess the response to treatment every 2 months. 
Tumor response was defined according to RECIST. PFS 
was defined as the period from the date of beginning treat-
ment until the date of disease progression or death from any 
cause, while OS was defined as the period from the date of 
beginning treatment until the date of last follow-up, death, 
or final follow-up day of evaluation.
statistical analysis
The median PFS of the first, second, third, and other lines 
of treatment were evaluated for the 120 patients included 
in the study. The normality of distribution was checked by 
using univariate indices of kurtosis and asymmetry with 
an acceptance threshold equal to 1. No variable violated 
normality indices. In order to provide a sociodemographic 
representation of the study group of patients and explore how 
to distribute the examined variables, descriptive statistical 
analyses were carried out. PFS and OS curves were estimated 
by using the Kaplan–Meier method. On the other hand, 
inferential statistical analyses were performed to detect any 
significant relationships among the considered variables. 
In particular, to analyze the correlation between PFS and 
OS, we used the linear correlation index of Bravais–Pearson 
(r) with a 95% confidence interval (CI). The relationship 
between the two variables was analyzed by linear regression 
(the OS represents the dependent variable Y and the PFS is 
the independent variable X). The values of the coefficient 
of determination R2 (which represents the proportion of 
variation between the observed values of Y explained by the 
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linear regression of Y on X) and the slope values (increase of 
Y for any increase of X units) were considered. Data were 
represented by scatter plot and regression line. Given the 
sample size, parametric statistics and a threshold of P,0.05 
value were used to evaluate the significance of the obtained 
results. Data processing was performed using the software 
Statistical Package for Social Science version 22.0.
Results
Treatment exposure and follow-up
In Table 1, we describe the demographic and clinical–
pathological characteristics of the 120 patients with MCRC 
included in this study. However, it is important to note that at 
the time of diagnosis, the age of patients was between 35 and 
80 years with a mean age of 58 years. About 87 patients had 
received the resection of the primary or one/two metastatic, 
46 patients had mucinous histology, 26 patients had received 
surgery and thermoablation for liver metastases, six patients 
had received surgical lung metastases, and most of the 
patients did not have severe comorbidity; patients with severe 
comorbidities were excluded from the sample.
Tolerability
In the group of patients treated with chemotherapeutic drugs 
administered in the third-line of treatment, the treatment-
related toxicity was not relevant and side effects were 
evaluated after each course of therapy and reported in line 
with the Cancer Therapy Evaluation Program Common 
Terminology Criteria for Adverse Events, version 4.0. Only 
20% of patients reported these relevant adverse events such 
as hand–foot skin reaction, diarrhea, and fatigue.
survival analysis
The median PFS of the first three lines of treatment 
were 8.5 months (range 4–23 months), 5 months (range 
4–7.5 months), and 3 months (range 2–5.5 months), 
respectively. Among the 120 patients enrolled, the interim 
analysis of survival (last follow-up in March 2017) showed 
a median OS of 32.4 months (range 12–38.5). The Bravais–
Pearson index allowed us to show a significant correlation 
between the PFS of the first-line treatment with Folfox–avastin 
and OS, with a value of r (95% CI) of 0.64 (0.25–0.81) and a 
P-value of 0.0021. Similar data were obtained in the second-
line treatment with Folfiri–avastin, with an r value (95% CI) 
of 0.60 (0.20–0.80) and a P-value of 0.0054. While in the 
third-line with regorafenib, no correlation between the PFS 
and OS was observed; the r value (95% CI) was 0.33 (-0.05 
to 0.68) and P=0.05 (Table 2). The regression analysis 
between PFS of the first-line of treatment with Folfox–avastin 
and OS showed an R2 value of 0.50 with a slope of 1.47 
(P=0.0021) (Figure 1). The linear regression between PFS 
of the second-line of treatment with Folfiri–avastin and OS 
showed an R2 value of 0.16 with a slope of 1.98 (P=0.080) 
(Figure 2). The regression analysis between PFS of the third-
line of treatment has not led to a statistically significant value 
(Figure 3). However, modest association between the PFS 
and OS was confirmed with regression analysis in the first 
two lines of treatment (Figures 1 and 2).
Discussion
Despite the common practice that OS still represents the 
primary endpoint for the most part of Phase III randomized 
Table 1 Baseline demographic and clinical characteristics (n=120)
Characteristics Patients
age at diagnosis (range), years 58 (35–80)
sex
Male 68
Female 52
Primary site 
colon
rectal 
87
33
size of metastasis
0.5–4 cm 85
4.5–5.5 cm 20
.6 cm 15
Metastatic site
liver 68
lung 39
Peritoneum 16
Table 2 Pearson’s correlation between progression-free survival 
(PFs) and overall survival (Os) in the three lines of treatment (n=120) 
Treatment line r value (95% CI) P-value
PFS first-line/OS 0.64 (0.25 to 0.81) P=0.0021
PFS second-line/OS 0.60 (0.20 to 0.80) P=0.0054 
PFS third-line/OS 0.33 (-0.05 to 0.68) P=0.05
? ?? ????
??
??
??
???
???
???
???
???
???????
???
?? ?? ?? ??
Figure 1 regression analysis between progression-free survival (PFs) and overall 
survival (OS) of patients in the first-line of treatment (N=120).
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trials, its use has several points of weakness, including a 
large number of patients in the studies, an extremely long 
time of follow-up, and the confounding role of subsequent 
lines of treatment. Therefore, the oncology community is 
investigating the potential role of new surrogate endpoints 
available for clinical use in order to promote a faster evalu-
ation of the effectiveness of new therapies,11,12 whereby very 
few have already shown a certain clinical validity. However, 
the definition of a surrogate endpoint is still a matter of 
debate. There is a general consensus on two points: first, a 
good correlation between the surrogate endpoint and the gold 
standard; second, the surrogate endpoint must be able to show 
the effect of treatment on the primary endpoint. A number 
of studies have evaluated the potential of new surrogate 
endpoints in different cancer settings13–15 and showed that 
PFS seems to be a good surrogate endpoint of OS in the 
evaluation of the treatment of MCRC.16,17 An analysis of the 
data collected from 11 randomized trials tested the validity 
of a number of potential surrogate endpoints of OS (tumor 
response, disease control, PFS, and time to progression) in 
the evaluation of the treatment of MCRC.18 Hellmann et al19 
have proposed the use of the pathological response as a sur-
rogate endpoint of survival in the evaluation of neoadjuvant 
treatment of non–small cell lung cancer.19 Other very signifi-
cant data have emerged from studies on surrogate endpoint 
of survival in the treatment of glioblastoma,20 renal cell 
carcinoma,21 and ovarian cancer.22 Despite the small sample 
of patients included in our study, we have shown that the 
PFS of the first-line treatment with Folfox–avastin may be a 
good surrogate endpoint of OS in patients with MCRC. Even 
if a strong correlation requires R2 values to be .0.90, it is 
clear that the first-line of treatment affects 40% of survival, 
or 60% considering only the data of deceased patients. The 
slope values indicate that an improvement of 1 month in PFS 
corresponds to about 2 months of OS benefit.23–25 The PFS 
of the third-line treatment with regorafenib showed a rather 
low level of correlation with the OS, accounting for only 
16% survival. However, the PFS of the second-line of treat-
ment with Folfori–avastin has moderate levels of correlation. 
In brief, our study found that the PFS of the first- and second-
lines of treatment could be a good candidate as a surrogate 
endpoint of OS in patients with MCRC. Our study allows us 
to conclude that PFS can be a variable surrogate endpoint in 
the first- and second-lines of treatment, in accordance with 
other clinical trials. The negative correlation obtained in the 
analysis of the third-line of treatment cannot be explained by 
a real lack of relationship between the variables examined, 
but rather by a shortage of studies dealing with the efficacy 
of PFS in targeted therapy.
In the third-line treatment, the survival time can be very 
short; hence, the correlation is not reliable as in the first-
line treatment. Since, in metastatic colorectal disease, today 
the survival exceeds 36 months from diagnosis, the use of 
surrogate endpoints can be useful, even if the standard still 
remains for the OS. For this reason, in the near future, a 
multicenter clinical trial including a larger pool of patients 
is needed to support the use of PFS to third-line treatment 
with target agents as a surrogate endpoint of OS.
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